Sermorelin has been given to children with growth hormone deficiency, compared head to head against growth hormone itself, and reviewed as a diagnostic and therapeutic agent. Ipamorelin’s only randomized human trial tested whether it got bowels moving after surgery. If your criterion is human evidence for the growth hormone axis, this comparison is not close, and almost every article ranking them gets it backwards because ipamorelin sounds newer.
The catch is that neither has what most people are buying them for, and that is worth saying before the detail.
Two different doors into the same gland
Growth hormone secretion is governed by GHRH, somatostatin and ghrelin acting in opposition.[1] These two compounds enter through different doors.
Sermorelin is growth hormone releasing hormone(1-29)-NH2, the first 29 amino acids of GHRH, and its pharmacokinetics and growth hormone stimulation were characterised in that form.[2] It is a fragment of the natural signal.
Ipamorelin is a growth hormone secretagogue receptor 1a agonist, acting at the ghrelin receptor.[3] A different receptor, a different signalling route into the same cells.
That difference matters more than it looks. Jaffe and colleagues showed that growth hormone responses to a pharmacological secretagogue required endogenous GHRH.[4] The ghrelin-receptor route is conditional on the GHRH route working. Sermorelin supplies the signal that ipamorelin depends on, which is an argument about sequence rather than about which is better.
Head to head on human evidence
This is the section that decides it.
Sermorelin has a clinical record. A study compared the growth response to GHRH(1-29)-NH2 directly against growth hormone itself in children,[5] and a review covers its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency.[6] Whatever you think of the indication, that is a compound taken through human studies with a measured clinical endpoint.
Ipamorelin has a founding paper and one trial in a different field. Raun and colleagues characterised it in 1998 as the first selective growth hormone secretagogue, releasing growth hormone without the cortisol response that earlier compounds produced.[7] Selectivity was the design goal and on that question it delivered.
Then the human programme went somewhere else entirely. The randomized controlled human trial of ipamorelin tested it as a ghrelin mimetic for postoperative gastrointestinal recovery,[8] not for growth hormone, not for body composition, not in healthy adults.
The asymmetry: sermorelin was studied for the growth hormone axis in people and has published clinical use. Ipamorelin’s one randomized human trial was about bowel function after surgery. Both facts are usually omitted from comparisons of the two.
What each delivers
On the only endpoint both share, growth hormone release, both work. That is not the interesting question.
The interesting question is what raising growth hormone does, and here the two are identical because they are the same axis:
Insulin sensitivity falls. A randomized study found insulin resistance induced by growth hormone, linked to lipolysis.[9] This is the axis behaving as designed, not an idiosyncratic reaction to either compound.
IGF-1 carries its own question. A meta-analysis of individual participant data found an association between circulating IGF-1 concentration and cancer risk.[10] Observational data on endogenous IGF-1 does not establish that raising it pharmacologically changes anyone’s risk, but it does put the burden of proof on the person arguing that years of deliberate elevation is free.
The outcome data is not flattering. A systematic review of growth hormone in the healthy elderly found increases in lean mass alongside higher rates of adverse events including oedema and joint pain.[11] That is direct growth hormone, at doses that certainly moved IGF-1, in the population with the most to gain.
That last one is the closest thing either compound has to a preview of the result people expect from them, and it came from pushing the axis harder than a secretagogue does.
Choose by what you are optimising for
Choose sermorelin if you want the compound with human clinical evidence. It has been given to patients, compared against growth hormone directly, and reviewed for a defined indication. That is more than almost any peptide in this category can say.
Choose ipamorelin if selectivity is the specific property you want. Its founding paper is about releasing growth hormone without the cortisol response earlier secretagogues produced, and that is a real and demonstrated advantage over its own predecessors. It is not an advantage over sermorelin, which is not in that class.
Choose neither on the strength of body composition claims. No randomized trial has measured body composition outcomes in healthy adults for either compound. Every physique-related claim attached to either is an extrapolation from a hormone measurement, and the one place the axis was pushed properly in healthy people produced small lean mass gains and real side effects.
Bottom line: sermorelin wins on human evidence and it is not close, because ipamorelin’s randomized human trial was about postoperative bowel recovery. Neither has been tested for the reason most people take them. If someone tells you ipamorelin is the more advanced option, ask which trial they are thinking of.
This article is for research and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The peptides discussed here are sold for research use only and are not for human consumption. Nothing in this article constitutes medical advice. Consult a qualified clinician before making changes to a health, training, or supplementation protocol.
References
The Complex World of Regulation of Pituitary Growth Hormone Secretion: The Role of Ghrelin, Klotho, and Nesfatins in It.. Frontiers in endocrinology, 2021.
Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration.. Acta paediatrica (Oslo, Norway : 1992). Supplement, 1993.
The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism.. Physiology & behavior, 2024.
Endogenous growth hormone (GH)-releasing hormone is required for GH responses to pharmacological stimuli.. The Journal of clinical investigation, 1996.
Growth response to growth hormone-releasing hormone(1-29)-NH2 compared with growth hormone.. Acta paediatrica (Oslo, Norway : 1992). Supplement, 1993.
Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency.. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 1999.
Ipamorelin, the first selective growth hormone secretagogue.. European journal of endocrinology, 1998.
Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.. International journal of colorectal disease, 2014.
A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk.. Cancer research, 2016.
Systematic review: the safety and efficacy of growth hormone in the healthy elderly.. Annals of internal medicine, 2007.
